hGH-CTP: Human Growth Hormone
Estimated 2010 worldwide market of $3.0 billion
Human Growth Hormone (hGH) is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone. The primary indications it treats in children are growth hormone deficiency, kidney disease, Prader-Willi Syndrome, and Turner's Syndrome.
PROLOR successfully completed a Phase II study of hGH-CTP in adults with growth hormone deficiency and released the results in 2011. The study results showed that a single injection of hGH-CTP could potentially replace 7 consecutive daily injections of commercially available hGH therapies. Safety and tolerability endpoints were met at all doses in all participants.
A Phase II study in growth hormone deficient children was initiated in 2012 and a Phase III study in adults with growth hormone deficiency is planned for 2013.